Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

M Rudwaleit, E Rødevand, P Holck, J Vanhoof, M Kron, S Kary, H Kupper

ABSTRACT

Objective: To evaluate the effect of adalimumab on the frequency of anterior uveitis (AU) flares in patients with active ankylosing spondylitis (AS).

Methods: We determined the history of ophthalmologist-diagnosed AU in 1250 patients with active AS who were enrolled in a multinational, open-label, uncontrolled clinical study of treatment with adalimumab, 40 mg every other week for up to 20 weeks. All AU flares were documented throughout the adalimumab treatment period plus 70 days. We compared the rates of AU flares per 100 patient years (PYs) reported during the year before adalimumab treatment with rates during adalimumab treatment, in total and by patient subgroups.

Results: The AU flare rates before adalimumab treatment were 15/100 PYs in all patients (n = 1250), 68.4/100 PYs in 274 patients with a history of AU flares, 176.9/100 PYs in 106 patients with a recent history of AU flares, 192.8/100 PYs in 28 patients with symptomatic AU at baseline and 129.1/100 PYs in 43 patients with a history of chronic uveitis. During adalimumab treatment, the rate of AU flares was reduced by 51% in all patients, by 58% in 274 patients with a history of AU, by 68% in 106 patients with a recent history of AU, by 50% in 28 patients with symptomatic AU at baseline and by 45% in 43 patients with chronic uveitis. AU flares during adalimumab treatment were predominantly mild. Two patients with periods of high AS disease activity had new-onset AU during the treatment period.

Conclusions: Results of this prospective open-label study suggest that adalimumab had a substantial preventive effect on AU flares in patients with active AS, including patients with a recent history of AU flares.

Clinical trials: ClinicalTrials.gov Identifier: NCT00478660.
Activity Index$^6$ (BASDAI) ≥4 despite treatment with at least one non-steroidal anti-inflammatory drug (NSAID) were enrolled. Previous treatment with another TNF antagonist was allowed if the therapy had been discontinued at least 3 weeks (for etanercept) or at least 2 months (for infliximab) before the first adalimumab injection. Ongoing treatment with NSAIDs including cyclo-oxyge2 nase 2 inhibitors, glucocorticoids (<10 mg/dl prednisolone equivalent) and/or DMARDs was allowed. The dosage regimen of current topical therapy with glucocorticoids or other agents in patients with uveitis could be tapered during the study.

**Study design**

This is a prespecified subanalysis of a multinational, prospective, open-label, uncontrolled clinical study of adalimumab 40 mg every other week for the treatment of patients with AS. Patients were enrolled at 211 clinical centres in 15 European countries. This study was approved by an independent ethics committee at each centre and all patients provided written, informed consent.

Details of the study design have been published elsewhere previously.$^7$ All patients were treated with adalimumab 40 mg every other week for 12 weeks. Patients with documented AU flares within 1 year before and/or at baseline continued receiving adalimumab up to week 20 to provide a longer observation period. Measures of adalimumab effectiveness were collected at weeks 2, 6, 12 and 20 (as applicable). At baseline, the history of ophthalmologist-diagnosed AU was confirmed in the medical record of each patient, and the AU was assessed as acute or chronic. Chronic uveitis was defined according to The Standardization of Uveitis Nomenclature Working Group as persistent AU flares (ie, ≥3 months in duration) with relapse occurring in the previous 3 months.$^8$ The number of recent AU flares (in the 12 months before and/or at baseline) were documented categorically as zero, one to two or three or more episodes. Any flare of AU that occurred during the adalimumab treatment period and up to 70 days after the last adalimumab injection was captured as an adverse event (AE).

In addition, advanced ankylosis at baseline, defined as at least Stage IV (involvement of ≥50% of the spine in ≥2 segments), was documented by the investigators based on historical radiographs.$^9$ The responses of spinal symptoms were evaluated by the Assessment in SpondyloArthritis International Society (ASAS) criteria as improvement by at least 20% (ASAS20) and by at least 40% (ASAS40),$^{10,11}$ ASAS 5/6 criteria (improvement of at least 20% in five of six ASAS criteria), ASAS partial remission (value of <2 on a 0–10-point scale in each of the four ASAS20 domains),$^{12,13}$ and improvement by at least 50% in the BASDAI (BASDAI 50).$^{14,15}$

**Statistical analyses**

The methodology for this prespecified analysis of AU flare rates was described in the clinical trial protocol and statistical analysis plan before enrolment of the first patient in the study. The rate of AU flares during the entire adalimumab treatment period (including the 70-day follow-up period) was calculated as events/100 patient years (PY) for all patients enrolled in the study (n = 1250), and for 4 subsets of patients. Three subsets were determined by the timing of AU activity with respect to the baseline study visit, as follows: patients with a history of uveitis (ie, at least one AU flare anytime in the course of their AS), patients with a recent AU flare (ie, at least one flare during the 12 months before and/or at baseline) and patients with symptomatic AU at baseline. The fourth subset was based on the clinical course of AU and included patients with chronic AU.

The rate of AU flares during adalimumab therapy was compared with the rate of AU flares in the 12 months before baseline per 100 PYs for all patients and the four subsets of patients with a Wilcoxon signed rank test. Because the number of flares in the past 12 months had been categorically documented (ie, 0, 1 to 2, or 3 or more episodes), the total number of flares was calculated by multiplying the number of patients in the 1–2 category by 1.5 (ie, the mean of the 1–2 category), and multiplying the number of patients in the ≥3 category by 3 (ie, the minimum number of episodes in this category). The ASAS40 and BASDAI 50 response rates at week 12 were compared in patients with vs without a history of uveitis, and also in patients without an AU flare vs patients with at least one AU flare during adalimumab treatment.

**RESULTS**

**Clinical characteristics and AU history**

Patients with active AS (n = 1250) had a mean disease duration of 11 years. A history of ophthalmologist-diagnosed AU was documented in 274 of 1250 (21.9%) enrolled patients. Of the 274 patients with AU, 45 had chronic uveitis; 106 had a recent history of uveitis and 28 had symptomatic AU at baseline.

The mean/median time of time from diagnosis of AU to study enrolment was 9.9/7.4 years in the 274 patients with a history of AU. The demographic and disease characteristics of all patients and of patients with a history of AU were generally similar. Sulfasalazine treatment was ongoing in 18% (56/274) of patients with a history of AU and in 10% (127/1250) of all patients. The percentages of patients with treatment with a previous TNF antagonist was 26% (326/1250) of all patients and 23% (63/274) of patients with a history of AU. The percentage of HLA-B27–positive patients was greater for patients with a history of uveitis than among the total study population or compared with patients without a history of uveitis, of whom 80% were HLA-B27 positive (data not shown). The serum concentration of C-reactive protein (CRP) was greater in patients with symptomatic AU at baseline compared with all other patient groups (table 1).

The majority of patients (84%, 231/274) had experienced acute AU and 16% (43/274) of patients had developed chronic uveitis. Among the 106 patients with a recent flare of AU, 26 (25%) had chronic uveitis. Among the 28 patients with symptomatic uveitis at baseline, 10 (36%) had a chronic uveitis (table 1).

**AU flare rates during the year prior to enrolment**

During the 12 months before and including the baseline visit, 87 patients had experienced 1 to 2 flares of AU and 19 patients had experienced 3 or more episodes of AU. The total number of AU flares in the year before and/or at baseline was 187.5. Accordingly, the AU flare rates per 100 PYs were 15 flares/100 PYs in all 1250 patients, 68.4 flares/100 PYs in the 274 patients with a history of uveitis and 176.9 flares/100 PYs in the 106 patients with a recent history of AU. The 28 patients with symptomatic AU at baseline had experienced 34 AU flares in the past year resulting in a rate of 192.9 flares/100 PYs. A total of 55.5 AU flares within the 1 year before adalimumab treatment was documented among the 43 patients diagnosed with chronic uveitis, for an AU flare rate in this group of 129.1 flares/100 PYs (table 2).
Adalimumab exposure

Among all 1250 patients in this study, the mean/median adalimumab exposure was 106/86 days. Overall, 115 of 1250 (9.2%) patients prematurely discontinued from the study. No patient discontinued adalimumab because of an AU episode. The mean/median duration of adalimumab treatment was 129/140 days in patients who had at least one AU flare in the 1 year before enrolment and who were observed up to week 20 by protocol.

Reduction of AU flare rates during adalimumab treatment

During 363 PYs of adalimumab treatment, 27 flares of AU were documented in 23 of 274 patients (8.4%) who had a recent history of AU. Of the 19 patients who had experienced 1 to 2 AU flares in the past year, 76 (87%) had no relapse of AU during adalimumab treatment. Of 87 patients who had experienced 3 or more AU flares in the past year, 46 (53%) had no relapse of AU during adalimumab treatment. Among the 28 patients with symptomatic AU at baseline, 19 (68%) experienced no AU flares during adalimumab treatment; 10 AU flares were reported in the other 9 patients.

Table 2  Anterior uveitis flare rates per 100 patient years before and during adalimumab therapy

| Patient groups by history of AU | AU flare rate before adalimumab treatment (flares/100 PYs) | AU flare rate during adalimumab treatment (flares/100 PYs) | Reduction in AU flare rate during adalimumab treatment (%) | p Value* |
|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------|
| All patients (n = 1250)        | 15                                                       | 7.4                                                      | −51                                                      | <0.001   |
| History of AU† (n = 274)       | 68.4                                                     | 28.9                                                     | −58                                                      | <0.001   |
| Recent history of AU‡ (n = 106) | 176.9                                                    | 56                                                       | −68                                                      | <0.001   |
| Symptomatic AU at baseline (n = 28) | 192.9                                                  | 96.2                                                     | −50                                                      | 0.001    |
| Previous chronic uveitis§ (n = 43) | 129.1                                                   | 71.4                                                     | −45                                                      | 0.002    |

*Wilcoxon signed rank test.
†History of AU, history of at least one AU flare anytime.
‡Recent history of AU, history of at least one AU flare in the past year.
§Chronic uveitis refers to persistent AU flares of at least 3-month duration and with relapse within less than 3 months according to the Standardization of Uveitis Nomenclature Working Group. AU, anterior uveitis; PYs, patient years.
In general, the percentage of patients who experienced an AU flare during adalimumab treatment was greater in patients with a history of chronic uveitis (21%, 9/45) than in patients with a history of acute AU (6%, 14/231). Each of the nine patients with chronic uveitis and with an AU flare during adalimumab treatment had experienced uveitis flares within the year before study enrolment.

Among all patients (n = 1250), 2 developed new-onset AU. In one patient, a mild AU flare occurred 4 days after the first adalimumab injection and ceased after 11 days topical non-steroidal treatment. Simultaneously with the remission of uveitis, the patient responded well to adalimumab, as indicated by a decrease in BASDAI from 6.3 at baseline to 1.1 at week 2. In the other patient, a moderate flare of AU occurred 90 days after initiation of adalimumab therapy. The AU flare in this patient was associated with a deterioration of AS activity, as suggested by an increase in BASDAI from 2.1 at week 6 to 4.7 at week 12 and by an increase of CRP concentration from 0.2 mg/dl at week 6 to 1.2 mg/dl at week 12.

The majority of AU flares that occurred during adalimumab treatment were reported as mild (67%) or moderate (29%); only one flare was considered severe by the treating doctor. All patients recovered from AU after topical anti-inflammatory treatment except for two patients with ongoing AU at the last observation. In one of these two patients, the AU flare had started 1 week after the last adalimumab injection; in the other patient, the onset of the AU flare was reported 2 months before the last observation. The time from first injection of adalimumab until onset of AU flares varied between 4 and 113 days, with a median interval of 72 days. The median duration of the 25 AU flare episodes that had a documented date of resolution was 22 days.

**ASAS and BASDAI responses**

The response of AS signs and symptoms to adalimumab was similar in all patients and in patients with a history of AU (table 3).

At week 12, 46% of the 25 patients who had an AU flare during adalimumab treatment achieved an ASAS40 response compared with 54% of the 1225 patients who had no AU flare during adalimumab treatment. The BASDAI 50 response rates were 56% of 25 patients who had an AU flare during adalimumab treatment and 57% of 1225 patients who had no AU flare during adalimumab treatment. Of the 25 patients who experienced an AU flare during adalimumab treatment, 7 (28%) were either insufficient responders with respect to their AS disease during the entire adalimumab treatment period, as indicated by a change from baseline in BASDAI <20%, or had a relapse of AS activity before the AU flare, indicated by at least a 50% increase in the BASDAI compared with the BASDAI score at the preceding study visit (data not shown). In three patients, the AU flare occurred during the 70-day follow-up period; therefore, no information on AS disease activity was available.

**DISCUSSION**

Our results suggest at least a 50% reduction in the AU flare rate during adalimumab treatment of patients with active AS. The results of this study are somewhat limited by the open-label, uncontrolled study design but are strengthened by the large number (>1000) of patients cared for in 211 centres in 15 European countries. Of the 1250 enrolled patients with AS, 274 had a history of AU. The AU flare rate of 15/100 PYs in all 1250 patients with AS before adalimumab treatment is similar to the AU flare rate of 15.6/100 PYs reported by Braun and colleagues in placebo-treated patients with AS from three pooled clinical trials of etanercept or infliximab for AS (the range among the three placebo groups varied from 0 to 37.2/100 PYs). Treatment with adalimumab decreased the rate of AU flares by 51% for all 1250 patients with AS to an AU flare rate of 7.4/100 PYs. By comparison, Braun and colleagues reported a pooled AU flare rate of 3.4/100 PYs for all infliximab-treated patients (range from 2.2 to 18.9/100 PYs in the three infliximab studies) and a pooled AU flare rate of 7.9/100 PYs for etanercept-treated patients (range from 0 to 9.6/100 PYs in four etanercept studies). Information about the AU flare rates before enrolment in these clinical studies of etanercept and infliximab was not collected.

For the 274 patients in this study with a history of AU, the rate of AU flares decreased by 58%, from 68.4/100 PYs to 28.9/100 PYs during adalimumab treatment. This rate is comparable to the rate of 21.4/100 PYs in a retrospective study of 46 TNF antagonist-treated patients with AS or with SpA. The majority of AU flares during the study were reported for those 106 patients who had a recent history of AU (ie, at least 1 flare within the past year). Nevertheless, in this subset of patients at high risk for relapse of AU, the rate of AU flares was reduced by 68% during adalimumab therapy. Also, in patients with a history of chronic uveitis, a reduction of AU flares during the study was observed. Most of the AU flares that occurred during adalimumab treatment were considered mild and subsided after 3 weeks in half of the patients in whom the duration of the AU flare was known.

**Table 3** Adalimumab effectiveness at week 12 in all patients and in patients with a history of anterior uveitis (observed values)

|                      | All patients (n = 1250) | History of AU* (n = 274) | Recent history of AU† (n = 106) | Symptomatic AU at baseline (n = 28) | Chronic AU‡ (n = 43) |
|----------------------|-------------------------|--------------------------|---------------------------------|------------------------------------|---------------------|
| ASAS40, %            | 53.7 (SD = 1.4)         | 54.5 (SD = 1.4)          | 55.1 (SD = 2.2)                 | 56.0 (SD = 2.4)                    | 52.4 (SD = 0.9)     |
| BASDAI 50, %         | 57.2 (SD = 1.8)         | 60.7 (SD = 1.8)          | 61.8 (SD = 2.0)                 | 66.7 (SD = 2.6)                    | 59.5 (SD = 0.3)     |
| ASAS partial remission, % | 27.7 (SD = 2.5)     | 32.5 (SD = 2.5)          | 32.7 (SD = 2.7)                 | 40.0 (SD = 3.0)                    | 33.3 (SD = 0.9)     |
| CRP, mg/dl, mean (SD)| 0.8 (SD = 1.4)          | 1.0 (SD = 1.8)           | 1.2 (SD = 2.2)                  | 1.6 (SD = 2.6)                     | 0.9 (SD = 0.9)      |
| CRP absolute change, mean (SD) | −1.4 (SD = 2.5)  | −1.9 (SD = 3.3)          | −2.3 (SD = 4.5)                 | −3.8 (SD = 5.5)                    | −2.6 (SD = 3.2)     |

*History of AU, history of at least one AU flare anytime.
†Recent history of AU, history of at least one AU flare in the past year.
‡Chronic uveitis refers to persistent AU flares of at least 3-month duration and with relapse within less than 3 months according to the Standardization of Uveitis Nomenclature Working Group.

ASAS, Assessments in Spondyloarthtitis International Society criteria for response, partial remission (value of ≤2 on a 0–10-point scale in each of the four ASAS20 domains); AU, anterior uveitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein.
The general therapeutic response of AS signs and symptoms in patients with a history of AU was comparable to the response of all patients in the study. The comparison of adalimumab effectiveness in patients with or without an AU flare during treatment is limited by the large difference in the number of patients in the 2 groups (25 who had an AU flare vs 1225 who did not) and because of the uncontrolled study design. However, an insufficient response or loss of response to adalimumab as measured by AS disease activity was documented in more than 25% of patients at the time of the AU flares. Nevertheless, most AU flares occurred in patients with a good overall clinical response to adalimumab, suggesting that vigilant monitoring for AU flares is necessary in patients with AS whose disease activity is low.

Two male patients developed an episode of new-onset unilateral AU. New-onset AU has been reported in adult and paediatric patients treated with etanercept and rarely in patients treated with infliximab. The underlying rheumatic disorders in patients with new-onset AU were often as related to idiopathic juvenile arthritis, or as related to juvenile idiopathic arthritis, and were more common in patients with a history of AU. Atypical bilateral AU flares were reported in six patients with AS during anti-TNF therapy (five patients with etanercept treatment, one patient with infliximab treatment). Because AU is frequently comorbid with AS, it is difficult to determine whether the underlying AS or the anti-TNF treatment has caused the new-onset AU. In one of the patients in the study, the first episode of AU occurred 4 days after the first adalimumab injection. Although a temporal relationship between adalimumab injection and the AU flare is apparent, this patient was in a state of high AS disease activity at the time of the flare. The same consideration is likely for the second patient who developed an AS flare 5 days before the first AU flare. On the other hand, the correlation between AS disease activity and the incidence of AU is generally considered to be low.2 During adalimumab treatment, the rate of AU flares was reduced by 51% in all patients, by 58% in patients with a history of AU, by 68% in patients with a recent history of AU, by 50% in patients with symptomatic AU at baseline and by 45% in patients with chronic uveitis. Most AU flares that occurred during adalimumab treatment were mild, and only two AU flares that occurred during adalimumab treatment were moderate.

CONCLUSIONS

Adalimumab effectively reduces the rate of AU flares in patients with active AS, including patients with recently symptomatic AU and patients with chronic uveitis.

Acknowledgements: We thank all principal investigators and research nurses who contributed to patient recruitment and data collection in RAHPDSYD. We are grateful to the following for enrolling at least three patients with anterior uveitis. Austria: Professor Dr M Herold (Innsbruck); Belgium: Dr J Vanhoof (Genk); Denmark: Dr K Grau (Kolding); Dr P Holtk (Silkeborg); France: Dr C Behamu (Orleans); Dr T Billie (Chahors); Dr D Brion (Aix-le-Bains); Professor Dr P Claudepierre (Clermont); Professor Dr P Farello (Amiens); Dr J Godde (Marseille); Dr JLG Grauer (Aix-en-Provence); Professor Dr A Saura (Brest); Germany: Professor Dr J Braun (Henne); Professor Dr G Hein (Jena); Professor Dr H Kellner (Munich); Professor Dr A Krause (Berlin); Dr K Rockwith (Goslar); Professor Dr A Rubbert-Roth (Konigshohe); Dr W Speier (Zurich); Dr H Trembl (Hamburg); Greece: Professor Dr D Bouroumis (Heraklion); Norway: Dr E Redved (Trondheim); Spain: Dr A Alonso (Barakaldo); Dr P Fernandes (Madrid); Dr E Le (Pampola); Dr C Rodriguez (Las Palmas de Gran Canaria); Switzerland: Dr R Theier (Zurich); UK: Dr E Choy (London); Dr R Cooper (Manchester); Dr C Edwards (Southampton); Professor Dr P Emery (Leeds); Dr A Keat (Harrow); Professor Dr R Moors (London). We also thank Ioanna Mantika for study management (both Abbott GmbH & Co KG, Germany); and Dana L Randall for editing the manuscript (JK Associates, Inc., Conshohocken, Philadelphia, USA).

Funding: The research reported here and the preparation of this manuscript was funded by Abbott Laboratories. The RAHPDSYD Study Group included experts from academic institutions in Europe and the USA and members of Abbott Laboratories who designed the original clinical trial. Clinical data were collected and analysed by Abbott Laboratories. All authors contributed to manuscript development and reviewed and approved the content of the submitted manuscript.

Competing interests: MR, ER, PH and JV were RAHPDSYD study investigators. MK and HK are employees of Abbott GmbH & Co KG, an affiliate of Abbott Laboratories. They hold shares of Abbott stock. SK is a contractor of Abbott GmbH.

Ethics approval: This study was approved by an independent ethics committee in each centre and all patients provided written, informed consent.

REFERENCES

1. Rosenberg JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002;20(Suppl 28):S143–5.
2. Hamidieh F, Frete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001;31:17–41.
3. Peto E, Banares J, Jouer JA, Fernandez-Gutierrez B, Godoy F, Morado C, et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000;27:2198–202.
4. Linder R, Hoffmann A, Brunner R. Prevalence of the spondylarthritides in patients with uveitis. J Rheumatol 2001;28:265–6.
5. Monnet D, Brecan M, Hudry C, Dougados M, Brézin AP. Ophthalmic findings and frequency of extracocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004;111:802–9.
6. Johns DA, Nussenblatt RB, Rosenberg JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509–16.
7. Benitez del Castillo JM, Garcia Sanchez J, Trader T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2002;16:340–3.
8. El-Shabrawy Y, Herrmann J. Anti-tumor necrosis factor-α therapy with infliximab as an alternative to corticosteroids in the treatment of human leucocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002;109:2342–6.
9. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson NJ, Whittcup SM, et al. Differential efficacy of tumor necrosis factor inhibitor in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252–7.
10. Smith JA, Thompson DJS, Whittcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18–21.
11. Sauremman RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrell PN, et al. Tumour necrosis factor-α inhibitors in the treatment of childhood uveitis. Rheumatology Oxford 2006;45:982–9.
12. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006;33:231–7.
13. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2006;52:2447–51.
14. Guignard S, Gosses L, Salliot C, Ruyen-Weitrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factors blockers in reducing uveitis flares in spondyloarthopathy: a retrospective study. Ann Rheum Dis 2008;65:1631–4.
15. Tilikakis AN, Tilikakis NA. Ocular inflammatory disease in patients with RA taking anti-TNF agents. Am J Ophthalmol 2003;135:925–6.
16. Hashkes PJ, Shahray I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003;21:545–6.
17. Reddy AR, Backhouse GC. Does etanercept induce uveitis? Br J Ophthalmol 2004;87:1205–6.
18. Foster CS, Tsujii F, Waheed NK, Chu D, Misericordia E, Baltazis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437–40.
19. Monnet D, Moachon L, Dougados M, Brézin AP. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2008;4:982–9.
20. Lim LL, Frankenfield FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248–52.
21. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
26. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 1994;21:2286–91.

27. Rudwaleit M, Claudepierre P, Wordsworth P, Loza E, Wong R, Kron M, et al. Predictors of major clinical responses (BASDAI50, ASAS40, ASAS partial remission) in 1,250 patients treated with adalimumab (HUMIRA) for active ankylosing spondylitis. *Ann Rheum Dis* 2008;67(Suppl 2):516.

28. Braun J, van der Heijde D, Dougados M, Emery P, Khan MA, Sieper J, et al. Staging of patients with ankylosing spondylitis: a preliminary proposal. *Ann Rheum Dis* 2002;61(Suppl 3):19–23.

29. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. *Arthritis Rheum* 2001;44:1876–86.

30. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNFα treatment. *Ann Rheum Dis* 2004;63:1438–44.

31. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. *Ann Rheum Dis* 2003;62:817–24.

32. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006;65:316–20.

33. Di Gangi M, Foti R, Leonardi R, Leonetti C, Castellino P. Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment. *Reumatismo* 2007;59:169–72.

34. Kuipiainen-Seppälä O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor α inhibitors. *Ann Rheum Dis* 2003;62:88–9.

35. Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. *Ann Rheum Dis* 2008;67:729–30.